The University of Oxford has launched the world's first Phase II trial for the ChAdOx1 NipahB vaccine in Bangladesh, in collaboration with icddr,b and funded by CEPI. Tested on 306 adults, it aims to assess safety and immune response against the deadly Nipah virus, which has a mortality rate of up to 75%.